Hepatitis C virus infection: a challenge in the complex management of two cases of multidrug-resistant tuberculosis
| العنوان: | Hepatitis C virus infection: a challenge in the complex management of two cases of multidrug-resistant tuberculosis |
|---|---|
| المؤلفون: | Gina Gualano, Fabrizio Palmieri, Maria Musso, Alessia Rianda, Franca Del Nonno, Rocco Urso, Silvia Mosti, Piero Ghirga, Paola Mencarini, Delia Goletti |
| المصدر: | BMC Infectious Diseases, Vol 19, Iss 1, Pp 1-4 (2019) BMC Infectious Diseases |
| بيانات النشر: | BMC, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | Adult, Male, medicine.medical_specialty, Tuberculosis, Drug-induced liver injury, Hepatitis C virus, Antitubercular Agents, Case Report, Hepacivirus, medicine.disease_cause, Chronic hepatitis C, Antiviral Agents, lcsh:Infectious and parasitic diseases, 03 medical and health sciences, 0302 clinical medicine, Medical microbiology, Multidrug-resistant tuberculosis, Internal medicine, Tuberculosis, Multidrug-Resistant, medicine, Humans, lcsh:RC109-216, 030212 general & internal medicine, Tuberculosis, Pulmonary, Aged, Liver injury, business.industry, Hepatitis C, Chronic, medicine.disease, Multiple drug resistance, Treatment, Regimen, Chronic infection, Infectious Diseases, Treatment Outcome, 030228 respiratory system, Parasitology, Italy, Retreatment, RNA, Viral, Female, Chemical and Drug Induced Liver Injury, business |
| الوصف: | Background Multidrug-resistant tuberculosis (MDR-TB) requires lengthy use of second-line drugs, burdened by many side effects. Hepatitis C virus (HCV) chronic infection increases risk of drug-induced liver injury (DILI) in these patients. Data on MDR-TB patients with concurrent HCV chronic infection treated at the same time with second-line antitubercular drugs and new direct-acting antivirals (DAAs) are lacking. We evaluate if treating at the same time HCV infection and pulmonary MDR-TB is feasible and effective. Cases presentation In this study, we described two cases of patients with pulmonary MDR-TB and concurrent HCV chronic infection cured with DAAs at a Tertiary Infectious Diseases Hospital in Italy. During antitubercular treatment, both patients experienced a DILI before treating HCV infection. After DAAs liver enzymes normalized and HCV RNA was undetectable. Then antitubercular regimen was started according to the institutional protocol, drawn up following WHO MDR-TB guidelines. It was completed without further liver side effects and patients were declared cured from both HCV infection and MDR-TB. Conclusions We suggest to consider treatment of chronic hepatitis C with DAAs as a useful intervention for reintroduction of second-line antitubercular agents in those patients who developed DILI, reducing the risk of treatment interruption when re-exposed to these drugs. |
| اللغة: | English |
| تدمد: | 1471-2334 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ddf7e369f934666fe82aa311efbfb24Test http://link.springer.com/article/10.1186/s12879-019-4494-1Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....5ddf7e369f934666fe82aa311efbfb24 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14712334 |
|---|